What is William Blair’s Forecast for AXSM FY2027 Earnings?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Equities researchers at William Blair reduced their FY2027 EPS estimates for shares of Axsome Therapeutics in a research note issued on Monday, November 3rd. William Blair analyst M. Minter now forecasts that the company will earn $10.79 per share for the year, down from their prior forecast of $11.91. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. William Blair also issued estimates for Axsome Therapeutics’ FY2028 earnings at $22.14 EPS and FY2029 earnings at $35.28 EPS.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). Axsome Therapeutics had a negative net margin of 49.88% and a negative return on equity of 283.22%. The company had revenue of $170.99 million for the quarter, compared to analyst estimates of $162.96 million. The company’s revenue was up 63.2% compared to the same quarter last year.

Several other research firms have also issued reports on AXSM. Morgan Stanley lifted their price target on shares of Axsome Therapeutics from $194.00 to $196.00 and gave the stock an “overweight” rating in a research report on Tuesday. B. Riley initiated coverage on Axsome Therapeutics in a research report on Wednesday, October 1st. They set a “buy” rating and a $179.00 target price on the stock. HC Wainwright boosted their target price on Axsome Therapeutics from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Tuesday. Guggenheim upped their price objective on shares of Axsome Therapeutics from $200.00 to $205.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Axsome Therapeutics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $180.75.

Axsome Therapeutics Stock Up 0.6%

AXSM opened at $135.69 on Thursday. Axsome Therapeutics has a one year low of $75.56 and a one year high of $139.13. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.51 and a current ratio of 1.57. The stock’s fifty day moving average is $124.02 and its 200-day moving average is $113.19. The company has a market capitalization of $6.77 billion, a PE ratio of -26.76 and a beta of 0.50.

Insiders Place Their Bets

In other Axsome Therapeutics news, CEO Herriot Tabuteau sold 21,775 shares of the business’s stock in a transaction dated Wednesday, November 5th. The stock was sold at an average price of $134.49, for a total value of $2,928,519.75. Following the transaction, the chief executive officer owned 7,229 shares in the company, valued at $972,228.21. The trade was a 75.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Mark L. Jacobson sold 10,000 shares of the business’s stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $115.96, for a total value of $1,159,600.00. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 407,271 shares of company stock valued at $50,640,415. Insiders own 22.30% of the company’s stock.

Hedge Funds Weigh In On Axsome Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Moors & Cabot Inc. increased its holdings in Axsome Therapeutics by 4.5% in the second quarter. Moors & Cabot Inc. now owns 2,330 shares of the company’s stock worth $243,000 after buying an additional 100 shares during the last quarter. Meridian Wealth Management LLC raised its holdings in shares of Axsome Therapeutics by 0.5% during the 3rd quarter. Meridian Wealth Management LLC now owns 22,124 shares of the company’s stock valued at $2,687,000 after purchasing an additional 103 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Axsome Therapeutics by 1.1% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 9,889 shares of the company’s stock valued at $1,032,000 after purchasing an additional 107 shares in the last quarter. Vanguard Personalized Indexing Management LLC raised its holdings in shares of Axsome Therapeutics by 6.8% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 2,101 shares of the company’s stock valued at $255,000 after purchasing an additional 134 shares in the last quarter. Finally, Mutual of America Capital Management LLC raised its holdings in shares of Axsome Therapeutics by 0.3% during the 1st quarter. Mutual of America Capital Management LLC now owns 39,623 shares of the company’s stock valued at $4,621,000 after purchasing an additional 136 shares in the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.